- Century Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
- Century Therapeutics Strengthens Position in Autoimmune Disease with Strategic Pipeline Expansion Supported by $60 Million Private Placement and Acquisition of Clade Therapeutics
- Century Therapeutics Presents New Preclinical Data Highlighting iPSC-derived Cell Therapy Platform Technology at the 2024 American Association for Cancer Research (AACR) Annual Meeting
- Century Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
- Century Therapeutics Reports Full Year 2023 Financial Results and Provides Business Updates
- Century Therapeutics Announces Six Upcoming Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting
- Century Therapeutics to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
- Century Therapeutics Presents Initial Data from CNTY-101 Phase 1 ELiPSE-1 Trial Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasion™ Edits
- Century Therapeutics to Host Conference Call to Discuss Preliminary Clinical Data from Phase 1 ELiPSE-1 trial of CNTY-101 in Relapsed or Refractory B-cell Lymphomas and Planned Phase 1 Study in Systemic Lupus Erythematosus
- Century Therapeutics Receives FDA Clearance of IND Application for CNTY-101 in Systemic Lupus Erythematosus
More ▼
Key statistics
On Monday, Century Therapeutics Inc (IPSC:NSQ) closed at 3.17, 147.66% above the 52 week low of 1.28 set on Nov 13, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.10 |
---|---|
High | 3.42 |
Low | 3.00 |
Bid | 3.01 |
Offer | 3.33 |
Previous close | 3.03 |
Average volume | 137.06k |
---|---|
Shares outstanding | 82.85m |
Free float | 59.24m |
P/E (TTM) | -- |
Market cap | 251.03m USD |
EPS (TTM) | -2.30 USD |
Data delayed at least 15 minutes, as of May 06 2024 21:00 BST.
More ▼